Sweden's Medivir Q1 revenue rises, EBITDA loss narrows

Medivir AB

05/05/2026 07:37

Overview

Sweden drug developer's Q1 revenue rose yr/yr, EBITDA loss narrowed

Company completed SEK 45 mln share issue to fund clinical development

Cash and cash equivalents rose to SEK 149.1 mln at quarter end

Outlook

Company plans to initiate phase 2 proof-of-concept study for MIV-711 in Osteogenesis Imperfecta

Randomized study of fostrox in second-line liver cancer is about to begin

Results from ongoing MIV-701 veterinary study expected in Q4 2026

Result Drivers

SHARE ISSUE - Directed share issue in February strengthened finances and enabled clinical development of MIV-711, per CEO Jens Lindberg

PIPELINE PROGRESS - Initiation and preparation of clinical studies for MIV-711 and fostrox advanced project portfolio, per CEO Jens Lindberg

Company press release: ID:nMFN7lZ1Sh

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
SEK 1 mln
Q1 Adjusted Free Cash Flow
-SEK 13 mln
Q1 EBITDA
-SEK 8.80 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Medivir AB is SEK5.50, about 192.6% above its May 4 closing price of SEK1.88

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)